Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

By: via Benzinga
Pharmacyclics (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.